000			02048 a2200601 4500
005			20250511212305.0
264		0	_c19910823
008			199108s 0 0 eng d
022			_a0041-1337
024	7		_a10.1097/00007890-199107000-00004 _2doi
040			_aNLM _beng _cNLM
100	1		_aSchmid, T
245	0	0	_aThe use of myocytes as a model for developing successful heart preservation solutions. _h[electronic resource]
260			_bTransplantation _cJul 1991
300			_a20-6 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAdenosine
650	0	4	_aAdenosine Triphosphate _xmetabolism
650	0	4	_aAllopurinol
650	0	4	_aAnimals
650	0	4	_aBicarbonates _xpharmacology
650	0	4	_aCell Survival _xdrug effects
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aGlucose _xpharmacology
650	0	4	_aGlutathione
650	0	4	_aHeart _xdrug effects
650	0	4	_aHypertonic Solutions _xpharmacology
650	0	4	_aIn Vitro Techniques
650	0	4	_aInsulin
650	0	4	_aL-Lactate Dehydrogenase _xbiosynthesis
650	0	4	_aMannitol _xpharmacology
650	0	4	_aModels, Biological
650	0	4	_aMyocardium _xmetabolism
650	0	4	_aOrgan Preservation _xmethods
650	0	4	_aOrgan Preservation Solutions
650	0	4	_aPolyethylene Glycols _xpharmacology
650	0	4	_aPotassium Chloride _xpharmacology
650	0	4	_aProcaine _xpharmacology
650	0	4	_aRabbits
650	0	4	_aRaffinose
650	0	4	_aRefrigeration _xadverse effects
650	0	4	_aRegression Analysis
650	0	4	_aSodium Chloride _xpharmacology
650	0	4	_aSolutions _xadverse effects
650	0	4	_aTime Factors
700	1		_aLandry, G
700	1		_aFields, B L
700	1		_aBelzer, F O
700	1		_aHaworth, R A
700	1		_aSouthard, J H
773	0		_tTransplantation _gvol. 52 _gno. 1 _gp. 20-6
856	4	0	_uhttps://doi.org/10.1097/00007890-199107000-00004 _zAvailable from publisher's website
999			_c1913238 _d1913238